69 results
Page 2 of 4
8-K
EX-99.1
41ff2u6w1s
4 May 23
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2023
4:11pm
8-K
EX-10.1
ftidb4 be3
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
EX-99.1
azm8fx
16 Dec 22
Lyell Immunopharma Appoints Lynn Seely, MD as President and Chief Executive Officer
4:02pm
8-K
EX-99.1
gctcekihi ayyqyc03wd
8 Nov 22
Lyell Immunopharma Reports Recent Business Highlights and Third Quarter Financial Results
4:07pm
8-K
9o9t3rmltvos pf
24 Oct 22
Termination of a Material Definitive Agreement
5:20pm
8-K
EX-99.1
xgcwyvcm wezwsj
6 Oct 22
Regulation FD Disclosure
4:37pm
S-3ASR
EX-1.2
m6jr6
4 Aug 22
Automatic shelf registration
5:29pm
S-3ASR
EX-4.4
i8hq8ycqlx8qpxe2mm9g
4 Aug 22
Automatic shelf registration
5:29pm
S-3ASR
rwc4cw37hy11nsp
4 Aug 22
Automatic shelf registration
5:29pm
8-K
EX-99.1
h19mlya2yi4rao6
4 Aug 22
Lyell Immunopharma Reports Second Quarter Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
vihs888u23w9bee
10 May 22
Lyell Immunopharma Reports First Quarter Financial Results and Business Highlights
4:14pm
S-8
otf62
29 Mar 22
Registration of securities for employees
4:56pm
10-K
l1ibhn
29 Mar 22
Annual report
4:20pm
8-K
EX-99.1
ranfi 1mgon
29 Mar 22
Lyell Immunopharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Highlights
4:15pm
8-K
EX-99.2
l51wac7bsbsaxc
17 Dec 21
Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs
4:02pm
8-K
rtpv52esedk44h
17 Dec 21
Lyell Immunopharma Announces cGMP Qualification of LyFE™ Manufacturing Center in Advance of Initiating Clinical Programs
4:02pm